Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Esophageal Neoplasms, Laryngeal Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03729518 2026-02-20

TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck

Phase NA Active not recruiting

150 enrolled

Head & Neck

Carcinoma, Squamous Cell, Oropharyngeal Neoplasms

NCT04150900 2026-02-19

1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck

Phase 2 Active not recruiting

7 enrolled 11 charts

Tumor-Agnostic

Carcinoma, Squamous Cell

NCT07419464 2026-02-19

5-Fluorouracil Response and Optimization STudy (The FROST Trial)

Phase 2 Not yet recruiting

46 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Laryngeal Diseases

Clinical Trials

Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery

Vitamin D Effects on Immune Microenvironment of Nonmelanoma Skin Cancer After Photodynamic Therapy (PDT)

Reflectance Confocal Microscopy of Oral Cancers in Vivo: a Preliminary Trial Comparing Intra-oral Imaging With Pathology

Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)

(NeoScorch HN)

DuTOC

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

INTLECTUAL

Rigosertib for RDEB-SCC

Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck

1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck

5-Fluorouracil Response and Optimization STudy (The FROST Trial)